Skip to main content
. Author manuscript; available in PMC: 2019 Oct 3.
Published in final edited form as: Diabet Med. 2019 Jul 7;36(9):1075–1081. doi: 10.1111/dme.14050

FIGURE 3.

FIGURE 3

FIGURE 3

FIGURE 3

Comparison of duration to diabetes onset to HbA1c, Type 1 diabetes associated antibodies at presentation, and human leukocyte antigen (HLA) following anti-programmed cell death protein-1 (PD-1) or anti-programmed cell death protein-1 ligand (PD-L1) inhibitor treatment. (a) Duration to Type 1 diabetes onset by HbA1c. (b) Duration to diabetes onset by Type 1 diabetes associated antibody positivity. Cases with a shorter duration to diabetes were more likely to present with diabetic ketoacidosis. (c) Duration to Type 1 diabetes onset by antibody positivity and the presence or absence of at-risk HLA genes.